8-K: Vivos Therapeutics Secures $7.5 Million Investment and Launches Strategic Alliance to Expand Sleep Apnea Treatment

Vivos Therapeutics has closed a $7.5 million private placement and formed a strategic alliance to market and distribute its sleep apnea treatments, marking a significant shift in its business model.

Summary

• Vivos Therapeutics has secured a $7.5 million private placement investment from V-CO Investors LLC, an affiliate of New Seneca Partners Inc.
• The investment includes the sale of 169,498 shares of common stock and warrants to purchase an additional 6,271,034 shares.
• The company will use the proceeds for general working capital and corporate purposes.
• Vivos has also entered into a strategic alliance with Rebis Health Holdings, LLC, a sleep testing and treatment center operator in Colorado.
• This alliance will allow Vivos to offer its sleep apnea treatments alongside other therapies, expanding its market reach.
• V-CO will provide management services to Vivos related to the strategic alliance, receiving a quarterly fee and a percentage of the net cash flow from the alliance.
• The company is required to file a registration statement for the resale of the shares by July 25, 2024, and to have it effective by September 8, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful capital raise and the strategic alliance, which are expected to drive future growth. The involvement of a private equity firm also adds credibility.

Positives

• The $7.5 million investment significantly bolsters Vivos' cash position and stockholders' equity.
• The strategic alliance with Rebis Health Holdings provides a new distribution channel for Vivos' products.
• The alliance is expected to increase revenue and lower patient acquisition costs.
• The management services agreement with V-CO provides expertise to maximize the revenue and profit from the alliance.
• The company has secured a private equity partner with experience in the healthcare space.
• Vivos has a scalable model that can be expanded nationally.

Negatives

• The company is required to file a resale registration statement, which could lead to dilution of existing shares.
• V-CO will receive a portion of the net cash flow from the alliance, which could reduce Vivos' overall profit.
• The management services agreement has a long term, potentially limiting flexibility.
• The company is dependent on the success of the strategic alliance to achieve profitability.

Risks

• The strategic alliance may not generate the expected revenue or profit.
• The company may not be able to expand the alliance model nationally.
• The company may not be able to achieve cash flow positivity and profitability.
• The company is subject to regulatory scrutiny and adverse publicity in the sleep apnea treatment sector.
• The investment by Seneca may not be sufficient for Vivos' long-term capital needs or to maintain its Nasdaq listing.

Future Outlook

Vivos expects the strategic alliance to be the first of many such alliances across the United States, which will drive revenue growth and lead to profitability. The company is also in talks with other sleep testing and therapy companies to expand this model nationally.

Management Comments

• Kirk Huntsman, Chairman and CEO of Vivos, stated that the alliance is of great importance to Vivos' future and is validated by the private equity investment from Seneca.
• Mr. Huntsman believes that Vivos has the most effective, safe, and potentially lasting non-surgical solution for all severities of OSA.
• Michael Skaff, Managing Director of Seneca, stated that they believe in the ability of Vivos' products to address OSA and in the new marketing and distribution model.
• Mr. Skaff also stated that their investment shows their commitment to this new endeavor for the long term.

Industry Context

This announcement reflects a trend in the medical device industry towards strategic partnerships and alliances to expand market reach and accelerate revenue growth. The focus on non-surgical solutions for sleep apnea aligns with patient preferences and the increasing demand for less invasive treatments.

Comparison to Industry Standards

• The strategic alliance model is similar to other medical device companies that partner with healthcare providers to distribute their products.
• The private placement investment is a common method for raising capital in the medical technology sector.
• The revenue-sharing model is a typical arrangement in strategic alliances.
• The management services agreement is similar to arrangements where private equity firms provide operational expertise to portfolio companies.
• The company's focus on non-surgical solutions for sleep apnea is a differentiator in the market, as many competitors focus on CPAP machines.

Stakeholder Impact

• Shareholders will benefit from the increased cash position and potential for revenue growth.
• Employees may benefit from the company's expansion and growth opportunities.
• Customers will have access to a more comprehensive range of sleep apnea treatment options.
• Suppliers may see increased demand for Vivos' products and services.
• Creditors may have increased confidence in the company's financial stability.

Next Steps

• Vivos will begin operations in two sleep treatment centers in Colorado in July 2024.
• Vivos will file a resale registration statement by July 25, 2024.
• Vivos will work to have the resale registration statement effective by September 8, 2024.
• Vivos will continue to seek additional strategic alliances with sleep testing and therapy companies.

Key Dates

Keywords

Vivos Therapeutics, sleep apnea, strategic alliance, private placement, New Seneca Partners, medical devices, oral appliances, healthcare, investment, revenue growth